

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities. Potential investors should read the prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.*



**CStone Pharmaceuticals**

**基石藥業**

*(Incorporated in the Cayman Islands with limited liability)*

**Stock Code: 2616**

## **MIXED MEDIA OFFER**

The Company will be issuing the prospectus on Thursday, February 14, 2019 in connection with the proposed Global Offering. An application has been made by the Company to the Listing Committee of the Stock Exchange for the granting of the approval for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the proposed Global Offering. Dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Tuesday, February 26, 2019.

The Company will be relying on Section 9A of the Companies (Exemption of Companies and prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong) and will be issuing the **WHITE** and **YELLOW** Application Forms without them being accompanied by a printed prospectus. The contents of the printed prospectus are identical to the electronic version of the prospectus which can be accessed and downloaded from the websites of the Company at [www.cstonepharma.com](http://www.cstonepharma.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the “*HKExnews > Listed Company Information > Latest Listed Company Information*” section, respectively.

Members of the public may obtain a copy of the printed prospectus, free of charge, upon request during normal business hours from 9:00 a.m. on Thursday, February 14, 2019 until 12:00 noon on Tuesday, February 19, 2019 at the following locations:

- any of the following branches of the receiving bank of the Company:

**Standard Chartered Bank (Hong Kong) Limited**

	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	188 Des Voeux Road Branch	Shop No. 7 on G/F Whole of 1/F - 3/F Golden Centre 188 Des Voeux Road Central Hong Kong
	Causeway Bay Branch	G/F to 2/F, Yee Wah Mansion 38-40A Yee Wo Street Causeway Bay
<b>Kowloon</b>	Mongkok Branch	Shop B, G/F, 1/F & 2/F 617-623 Nathan Road Mongkok
	68 Nathan Road Branch	Basement, Shop B1 G/F and M/F Golden Crown Court 66-70 Nathan Road Tsimshatsui
<b>New Territories</b>	Yuen Long Fung Nin Road Branch	Shop B at G/F and 1/F Man Cheong Building 239-247&247A Castle Peak Road Yuen Long

- any of the following offices of the Hong Kong Underwriters:

<b>Hong Kong Underwriters</b>	<b>Address</b>
Goldman Sachs (Asia) L.L.C.	59/F, Cheung Kong Center 2 Queen's Road Central Hong Kong
Morgan Stanley Asia Limited	46/F, International Commerce Centre 1 Austin Road West Kowloon Hong Kong
UBS AG Hong Kong Branch	52/F, Two International Finance Centre 8 Finance Street Central Hong Kong
China Merchants Securities (HK) Co., Limited	48/F, One Exchange Square Central Hong Kong

- the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

**Details of where printed prospectuses may be obtained will be displayed prominently at every location where WHITE and YELLOW Application Forms are distributed.**

During normal business hours from 9:00 a.m. on Thursday, February 14, 2019 until 12:00 noon on Tuesday, February 19, 2019, at least three copies of the printed prospectus will be available for inspection at every location where the **WHITE** and **YELLOW** Application Forms are distributed as set out in “*How to Apply for Hong Kong Offer Shares*” in the prospectus.

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below:

“Application Form(s)”	the <b>WHITE</b> Application Form(s), <b>YELLOW</b> Application Form(s) and <b>GREEN</b> Application Form(s) relating to the Hong Kong Public Offering or, where the context so requires, any of them
“Board”	the board of directors of the Company
“Company”	CStone Pharmaceuticals, an exempt company incorporated under the laws of the Cayman Islands with limited liability on December 2, 2015
“Director(s)”	the director(s) of the Company
“Global Offering”	the Hong Kong Public Offering and the International Offering
“HKSCC”	Hong Kong Securities Clearing Company Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Hong Kong Public Offering”	the offer of the Hong Kong Offer Shares for subscription by the public in Hong Kong, on the terms and subject to the conditions described in this prospectus and the Application Forms relating thereto, as further described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering” in the prospectus
“International Offering”	the conditional placing of the International Offer Shares at the Offer Price outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and in the United States to QIBs only in reliance on Rule 144A or any other available exemption from the registration requirement under the U.S. Securities Act, in each case on and subject to the terms and conditions of the International Underwriting Agreement, as further described in the section headed “Structure of the Global Offering” in the prospectus

“Joint Global Coordinators”	Goldman Sachs (Asia) L.L.C., Morgan Stanley Asia Limited, UBS AG Hong Kong Branch and China Merchants Securities (HK) Co., Limited
“Listing Committee”	the listing committee of the Stock Exchange
“Listing Date”	the date, expected to be on or about Tuesday, February 26, 2019, on which the Shares are listed and from which dealings therein are permitted to take place on the Stock Exchange
“prospectus”	the prospectus to be issued on Thursday, February 14, 2019 by the Company
“Shares”	ordinary shares of US\$0.0001 each in the issued share capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“U.S. Securities Act”	the United States Securities Act of 1933, as amended
“United States”	the United States of America, its territories and possessions, any state of the United States and the District of Columbia

By order of the Board  
**CStone Pharmaceuticals**  
**Dr. Frank Ningjun Jiang**  
*Chairman*

Hong Kong, February 13, 2019

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and Executive Director; Dr. Wei Li, Mr. Qun Zhao, Mr. Xiaomeng Tong, Mr. Guobin Zhang and Dr. Lian Yong Chen as Non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as Independent Non-executive Directors\*.*

\* *Effective date of appointment of the Independent Non-executive Directors is February 14, 2019*